GLP-1 obesity trials shift focus from weight loss to broader hepatic, cardiometabolic, and inflammatory outcomes
Background
The global epidemic of obesity presents a significant public health challenge, driving increased risk for numerous comorbidities including type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. Current pharmacological interventions often fall short of achieving sustained, clinically meaningful weight loss with comprehensive metabolic benefits. Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a cornerstone in obesity management, demonstrating efficacy in weight reduction and improved glycemic control. Understanding the evolving landscape of clinical research into GLP-1-based interventions is crucial to identify emerging therapeutic targets and optimize future drug development strategies.
Study Design
Researchers conducted a registry-based cross-sectional qualitative analysis of ClinicalTrials.gov data, retrieved on October 18, 2025. The study identified 227 completed interventional trials evaluating GLP-1 receptor agonists, including liraglutide, semaglutide, tirzepatide, exenatide, dulaglutide, and lixisenatide, for obesity. Key variables extracted included study phase, intervention type, enrolment numbers, primary outcomes, and completion year. Descriptive statistics summarized quantitative data, while qualitative thematic synthesis categorized outcome domains and research focus.
Results
A total of 227 completed interventional studies investigating GLP-1-based interventions for obesity were identified. Liraglutide was the most frequently investigated agent, accounting for n = 86 trials. Semaglutide and tirzepatide followed, each investigated in n = 18 trials, with exenatide in n = 15 trials, and other GLP-1 analogues comprising the remainder. Phase 3 and 4 trials predominated the landscape, indicating a mature stage of clinical development for many agents. Most studies enrolled fewer than 200 participants, suggesting a focus on specific populations or early-stage efficacy. Primary outcomes, while still largely weight-related, showed a significant expansion. > There was increasing attention to hepatic, cardiometabolic, and inflammatory endpoints, signaling a broader understanding of GLP-1's pleiotropic effects beyond simple weight and glycemic control. A marked rise in completed trials was observed after 2018, coinciding with the market introduction and increased research into newer, more potent GLP-1 analogues.
Key Findings
- 227 completed interventional GLP-1 obesity trials were identified on ClinicalTrials.gov.
- Liraglutide was the most investigated agent (n = 86 trials).
- Phase 3 and 4 trials predominated, with most studies enrolling fewer than 200 participants.
- Primary outcomes expanded from weight-related to include hepatic, cardiometabolic, and inflammatory endpoints.
- A marked rise in completed GLP-1 trials was observed after 2018.
Why It Matters
This analysis highlights a critical shift in the clinical research paradigm for GLP-1 agonists in obesity, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific benefits. Clinicians and researchers should recognize the expanding therapeutic potential of GLP-1s for conditions like MASLD, cardiovascular disease, and chronic inflammation. This evolving focus suggests that future GLP-1 protocols may increasingly target these comorbidities directly, potentially leading to combination therapies or tailored regimens for specific patient profiles. The observed increase in trials post-2018 underscores the rapid innovation in this class, indicating a robust pipeline for next-generation GLP-1-based interventions with broader systemic impact.